Tetraphase Pharmaceuticals, Inc. (TTPH) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) have been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $11.80.
A number of analysts have recently issued reports on the stock. Stifel Nicolaus restated a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Tuesday. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 30th. Piper Jaffray Companies assumed coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday, August 28th. They set an “overweight” rating and a $14.00 target price for the company. Finally, BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd.
Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 6.88 on Friday. The company’s market cap is $351.24 million. The stock’s 50 day moving average is $6.28 and its 200 day moving average is $7.26. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.47) EPS. On average, equities analysts forecast that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current year.
In related news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00. Following the transaction, the insider now directly owns 17,500 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.50% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. AXA bought a new position in Tetraphase Pharmaceuticals during the second quarter worth about $132,000. Teza Capital Management LLC increased its position in Tetraphase Pharmaceuticals by 8.9% during the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,281 shares during the period. Citadel Advisors LLC increased its position in Tetraphase Pharmaceuticals by 18.6% during the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 2,496 shares during the period. Virtu KCG Holdings LLC bought a new position in Tetraphase Pharmaceuticals during the second quarter worth about $147,000. Finally, Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 3,104 shares during the period. 41.73% of the stock is currently owned by institutional investors and hedge funds.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.